# MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

> **NCT00326456** · PHASE3 · UNKNOWN · sponsor: **National Cancer Institute, Naples** · enrollment: 820 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** liposomal doxorubicin
- **DRUG:** carboplatin
- **DRUG:** paclitaxel

## Key facts

- **NCT ID:** NCT00326456
- **Lead sponsor:** National Cancer Institute, Naples
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2003-01-01
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 820 (ACTUAL)
- **Last updated:** 2023-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326456, "MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00326456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*